OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.
- Written by PR Newswire
 |
- OMLYCLO® (omalizumab-igec) is the first and onlyFDA-approved omalizumab biosimilar approved for all four indications of XOLAIR® (omalizumab) and designated as interchangeable with XOLAIR; OMLYCLO® will be available in 75 mg/0.5 mL, 150 mg/mL and 300mg/2mL in a single-dose prefilled syringe for subcutaneous injection in the U.S.
- The...
